American Association for Cancer Research
Browse

Supplementary Figures 1-7 from Malignant Progression of an Ancestral Bone Marrow Clone Harboring a <i>CIC-NUTM2A</i> Fusion in Isolated Myeloid Sarcoma

Download (786.25 kB)
journal contribution
posted on 2023-04-03, 08:41 authored by Jennifer L. Kamens, Jinjun Dang, Timothy I. Shaw, Alexander M. Gout, Scott Newman, Kohei Hagiwara, Amelia M.R. Smith, Alyssa N. Obermayer, Sarah Aldridge, Jing Ma, Yang Zhang, Gang Wu, Vasiliki Leventaki, Teresa Santiago, Susana Raimondi, Joy Nakitandwe, Alberto Pappo, Chunliang Li, Jinghui Zhang, Tanja A. Gruber
<p>Supplementary Methods and FiguresSupplementary Figure 1. A newborn with isolated myeloid sarcoma.Supplementary Figure 2. Myeloid Sarcoma Histology.Supplementary Figure 3. Bone Marrow.Supplementary Figure 4. Genes Upregulated in CIC-NUTM2A.Supplementary Figure 5. Differential Serial Re-plating Capacity of NUT Family Members.Supplementary Figure 6. Gene Expression Analysis of CIC-NUTM2A Signature.Supplementary Figure 7. Receptor Tyrosine Kinase Signaling.</p>

Funding

American Lebanese Syrian Associated Charities (ALSAC)

History

Related Materials

  1. 1.
    DOI - Is supplement to Malignant Progression of an Ancestral Bone Marrow Clone Harboring a CIC-NUTM2A Fusion in Isolated Myeloid Sarcoma

ARTICLE ABSTRACT

Myeloid sarcoma is a rare condition consisting of extramedullary myeloid blasts found in association with acute myeloid leukemia or, in the absence of bone marrow involvement. We identified an infant with isolated myeloid sarcoma whose bone marrow was negative for involvement by flow cytometry. Sequencing revealed the fusion oncogene CIC-NUTM2A and identified the sarcoma to be clonally evolved from the bone marrow, which carried the fusion despite the absence of pathology. Murine modeling confirmed the ability of the fusion to transform hematopoietic cells and identified receptor tyrosine kinase (RTK) signaling activation consistent with disruption of the CIC transcriptional repressor. These findings extend the definition of CIC-rearranged malignancies to include hematologic disease, provide insight into the mechanism of oncogenesis, and demonstrate the importance of molecular analysis and tracking of bone marrow involvement over the course of treatment in myeloid sarcoma, including patients that lack flow cytometric evidence of leukemia at diagnosis. This study illustrates molecular involvement of phenotypically normal bone marrow in myeloid sarcoma, which has significant implications in clinical care. Further, it extends the definition of CIC-rearrangements to include hematologic malignancies and shows evidence of RTK activation that may be exploited therapeutically in cancer(s) driven by these fusions.

Usage metrics

    Molecular Cancer Research

    Categories

    Keywords

    cancer

    Licence

    CC BY

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC